Item 2.02 Results of Operations and Financial Condition.

On January 20, 2022, BioDelivery Sciences International, Inc. (the "Company") issued a press release announcing that its net revenue, BELBUCA net sales and EBITDA for the full year 2021 were expected to come in at the high end of or exceed previously announced guidance. A copy of the press release is being furnished as Exhibit 99.1 to this Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits.





(d) Exhibits
   Exhibit
     No.            Description
    99.1              Press release issued by the Company on January 20, 2022, furnished herewith

     104            Cover Page Interactive Data File (embedded within the Inline XBRL document
                    contained in Exhibit 104)

© Edgar Online, source Glimpses